Qianhai Health Holdings Limited (0911.HK)
HKD 0.27
(0.0%)
HKD 0.27
(0.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 961.29 Million HKD | -51.0% |
| 2022 | 1.96 Billion HKD | 592.21% |
| 2021 | 283.39 Million HKD | -62.75% |
| 2020 | 760.72 Million HKD | 29.42% |
| 2019 | 587.8 Million HKD | 653.15% |
| 2018 | 78.04 Million HKD | -60.39% |
| 2017 | 197.06 Million HKD | -44.39% |
| 2016 | 354.38 Million HKD | -57.59% |
| 2015 | 835.53 Million HKD | -31.49% |
| 2014 | 1.21 Billion HKD | 59.86% |
| 2013 | 762.97 Million HKD | 54.99% |
| 2012 | 492.27 Million HKD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 153.48 Million HKD | 0.0% |
| 2024 Q1 | 153.48 Million HKD | -75.3% |
| 2023 Q3 | 310.69 Million HKD | -8.59% |
| 2023 Q1 | 169.94 Million HKD | -77.65% |
| 2023 FY | 961.29 Million HKD | -51.0% |
| 2023 Q4 | 621.39 Million HKD | 100.0% |
| 2023 Q2 | 339.89 Million HKD | 100.0% |
| 2022 Q4 | 760.42 Million HKD | 100.0% |
| 2022 Q3 | 380.21 Million HKD | -68.35% |
| 2022 Q1 | 600.63 Million HKD | 585.0% |
| 2022 FY | 1.96 Billion HKD | 592.21% |
| 2022 Q2 | 1.2 Billion HKD | 100.0% |
| 2021 Q4 | 87.68 Million HKD | 100.0% |
| 2021 FY | 283.39 Million HKD | -62.75% |
| 2021 Q1 | 97.85 Million HKD | -73.62% |
| 2021 Q2 | 195.71 Million HKD | 100.0% |
| 2021 Q3 | 43.84 Million HKD | -77.6% |
| 2020 Q1 | 194.89 Million HKD | -63.58% |
| 2020 Q2 | 389.79 Million HKD | 100.0% |
| 2020 Q3 | 185.46 Million HKD | -52.42% |
| 2020 Q4 | 370.92 Million HKD | 100.0% |
| 2020 FY | 760.72 Million HKD | 29.42% |
| 2019 Q4 | 535.16 Million HKD | 100.0% |
| 2019 Q2 | 52.64 Million HKD | 100.0% |
| 2019 Q1 | 26.32 Million HKD | 34.8% |
| 2019 FY | 587.8 Million HKD | 653.15% |
| 2019 Q3 | 267.58 Million HKD | 408.25% |
| 2018 FY | 78.04 Million HKD | -60.39% |
| 2018 Q4 | 19.52 Million HKD | 0.0% |
| 2018 Q3 | 19.52 Million HKD | 0.17% |
| 2018 Q2 | 19.49 Million HKD | 0.0% |
| 2018 Q1 | 19.49 Million HKD | -53.66% |
| 2017 Q1 | 56.45 Million HKD | 2.29% |
| 2017 FY | 197.06 Million HKD | -44.39% |
| 2017 Q2 | 56.45 Million HKD | 0.0% |
| 2017 Q4 | 42.07 Million HKD | 0.0% |
| 2017 Q3 | 42.07 Million HKD | -25.48% |
| 2016 Q4 | 55.19 Million HKD | 0.0% |
| 2016 Q3 | 55.19 Million HKD | -54.75% |
| 2016 Q2 | 121.99 Million HKD | 0.0% |
| 2016 Q1 | 121.99 Million HKD | 159.56% |
| 2016 FY | 354.38 Million HKD | -57.59% |
| 2015 Q2 | 622.58 Million HKD | 0.0% |
| 2015 Q3 | -204.81 Million HKD | -132.9% |
| 2015 FY | 835.53 Million HKD | -31.49% |
| 2015 Q1 | 622.58 Million HKD | 238.47% |
| 2015 Q4 | -204.81 Million HKD | 0.0% |
| 2014 Q3 | 183.94 Million HKD | -56.81% |
| 2014 Q1 | 425.88 Million HKD | 297.13% |
| 2014 FY | 1.21 Billion HKD | 59.86% |
| 2014 Q4 | 183.94 Million HKD | 0.0% |
| 2014 Q2 | 425.88 Million HKD | 0.0% |
| 2013 Q2 | 274.24 Million HKD | 0.0% |
| 2013 Q4 | 107.23 Million HKD | 0.0% |
| 2013 Q3 | 107.23 Million HKD | -60.9% |
| 2013 Q1 | 274.24 Million HKD | 43.78% |
| 2013 FY | 762.97 Million HKD | 54.99% |
| 2012 FY | 492.27 Million HKD | 0.0% |
| 2012 Q4 | 190.74 Million HKD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 259.15 Million HKD | -270.929% |
| Grand Pharmaceutical Group Limited | 10.52 Billion HKD | 90.871% |
| Extrawell Pharmaceutical Holdings Limited | 59.09 Million HKD | -1526.605% |
| Wai Yuen Tong Medicine Holdings Limited | 783.88 Million HKD | -22.632% |
| Lee's Pharmaceutical Holdings Limited | 1.05 Billion HKD | 8.712% |
| Essex Bio-Technology Limited | 1.7 Billion HKD | 43.671% |
| Tongfang Kontafarma Holdings Limited | 809.1 Million HKD | -18.809% |
| PuraPharm Corporation Limited | 406.85 Million HKD | -136.271% |
| SSY Group Limited | 6.46 Billion HKD | 85.126% |
| JBM (Healthcare) Limited | 648.41 Million HKD | -48.252% |
| Jacobson Pharma Corporation Limited | 1.46 Billion HKD | 34.508% |
| China Resources Pharmaceutical Group Limited | 270.39 Billion HKD | 99.644% |